Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Summary
Third Opinion Trial Synopsis:
We want to see how well a medicine called Descartes-08 works for people with a type of cancer called high-risk myeloma. We want to know if it can get rid of the leftover cancer cells after their first treatment. We call it Minimal Residual Disease-negative Complete Response.
We want to see how well a medicine called Descartes-08 works for people with a type of cancer called high-risk myeloma. We want to know if it can get rid of the leftover cancer cells after their first treatment. We call it Minimal Residual Disease-negative Complete Response.
*Third Opinion AI Generated Synopsis
Trial Summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
